Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.77 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.77 |
| ▸ | GSK3A | P49840 | 1/20 | 0.65 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.65 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.65 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | ROS1 | P08922 | 1/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27238014 | 1.00 | EGFR (0.77) | EGFRLRRK2GSK3AMAPK15CAMKK2 | |
| SCHEMBL30942576 | 0.91 | EGFR (0.77) | EGFRLRRK2ALKROS1 | |
| SCHEMBL27238002 | 0.88 | EGFR (0.73) | EGFRLRRK2GSK3AMAPK15CAMKK2 | |
| SCHEMBL29429981 | 0.87 | EGFR (1.00) | EGFRLRRK2GSK3AMAPK15CAMKK2 | |
| SCHEMBL1460537 | 0.87 | EGFR (1.00) | EGFRLRRK2GSK3AMAPK15CAMKK2 | |
| Hydrochloric Acid SCHEMBL29429990 | 0.86 | EGFR (0.98) | EGFRLRRK2GSK3AMAPK15CAMKK2 | |
| Hydrochloric Acid SCHEMBL17262629 | 0.86 | EGFR (0.98) | EGFRLRRK2GSK3AMAPK15CAMKK2 | |
| SCHEMBL23248551 | 0.86 | EGFR (0.70) | EGFRLRRK2GSK3AMAPK15CAMKK2 | |
| SCHEMBL23304015 | 0.86 | EGFR (1.00) | EGFRLRRK2GSK3AMAPK15CAMKK2 | |
| SCHEMBL28728686 | 0.82 | ZAP70 (0.60) | EGFRLRRK2CAMKK2ZAP70ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-10-17 | — | — | US | disclosed |
| EP-4382514-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2024-06-12 | — | — | EP | disclosed |
| CN-118139847-A | Pyrimidine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2024-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | ERBB2, EGFR, DPYD | EGFR 2/4885LRRK2 1303/4885GSK3A 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.